Clinical trial
OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or…
NCT00130403 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00130403 |
|---|---|
| Title | OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women |
| Official title | Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoporosis, Postmenopausal |
| Intervention type | Drug |
| Interventions | risedronate sodium |
| Enrollment | 290 |
| Start date | Mar 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Aug 15, 2005 |
| Last update posted | Jan 11, 2011 |
| Countries | Australia, Belgium, Canada, France, Netherlands, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: